Progenics (PGNX), Valeant (VRX) OIC Drug Gets FDA Greenlight; Intuitive Surgical (ISRG) Delivers Above-Consensus Profits
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) shares soared over 30% in after-hours trading Tuesday as the company said that the U.S. Food and Drug Administration (FDA) gave green light to its partnered opioid-induced constipation (OIC) treatment RELISTOR – Tablets, 450 mg once daily – in adults with chronic non-cancer pain.
Canadian drug maker Valeant Pharmaceuticals International, Inc. (NYSE:VRX) – which has an exclusive license and rights to develop and commercialize RELISTOR from Progenics – expects to start U.S. sales of RELISTOR Tablets during the third quarter 2016
PGNX stock finished the regular session in negative territory by 8.52% (or -$0.46) at $4.94, with a total volume of 3.47M shares traded
Progenics, which is engaged in developing medicines and other products for targeting and treating cancer, has 69.95M Shares Outstanding and PGNX stock one-year range is between $3.61 and $11.15 per share. At close on Tuesday, the oncology company had a Market Capitalization of $365.86M.
Shares of Intuitive Surgical, Inc. (Nasdaq:ISRG) climbed more than 6% to reach a new 52-week high in the extended session Tuesday after the company delivered in its financial results quarterly profit and revenue numbers above Wall Street analysts’ expectations
For the second quarter 2016, Intuitive Surgical posted revenue of $670.1 million, a 14.33% increase year over year, and non-GAAP net income of $220 million, or $5.62 per diluted share, compared with non-GAAP net income of $173 million, or $4.57 per diluted share in the same quarter the prior year, easily surpassing the Capital IQ Consensus Estimate of $4.99 earnings per share on revenues of $642.46 million for the period
ISRG stock closed at $671.90, up $1.36 (or +0.20%) and 456,418 shares of the company changed hands during the day
Intuitive Surgical, which develops, manufactures, and markets the da Vinci Surgical System, has 38.06M Shares Outstanding, Market Capitalization (intraday) of $25.58B and ISRG stock one-year range is from $447.00 to $681.59 per share
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com